$4.66
Value $235M
CUVL and MSFT stock compared: price, dividend, valuation and results, from SEC filings.
$4.66
Value $235M
$484.02
Value $3.59T
Clinuvel Pharmaceuticals (CUVL) has a market value of $235M and Microsoft (MSFT) $3.59T. Over the last year, with dividends, CUVL moved -32.5% and MSFT +0.4%. The P/E is 10.1 for CUVL and 25.2 for MSFT. Dividend yield: CUVL 0.71%, MSFT 0.77%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CUVL$235M
MSFT$3.59T
MSFT is 15,294 times CUVL
Revenue, 12 months
CUVL$64M
MSFT$346B
MSFT is 5,387 times CUVL
Net income, 12 months
CUVL$23M
MSFT$143B
MSFT is 6,154 times CUVL
Operating margin
CUVL43.4%
MSFT47.1%
3.7 points apart
ROIC
CUVL11.7%
MSFT28.7%
17.0 points apart
P/E
CUVL10.1
MSFT25.2
MSFT is 2.5 times CUVL
Dividend yield
CUVL0.7%
MSFT0.8%
0.1 points apart
5-year return
CUVL-79.3%
MSFT+47.0%
126.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CUVL-79.3%
MSFT+47.0%
| Period | CUVLWith dividends | MSFTWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | -32.5%Price -32.9% | +0.4%Price -0.6% |
| 3 years since November 20, 2023 | -54.9%-23.3% a yearPrice -55.3% | +31.2%+9.5% a yearPrice +28.2% |
| 5 years since November 19, 2021 | -79.3%-27.0% a yearPrice -79.6% | +47.0%+8.0% a yearPrice +41.1% |
| 10 years since November 21, 2016 | -20.9%-2.3% a yearPrice -22.3% | +791.5%+24.5% a yearPrice +695.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CUVLClinuvel PharmaceuticalsMSFTMicrosoft
| Price | $4.66 | $484.02 |
|---|---|---|
| Market value | $235M | $3.59T |
| Enterprise value (EV) | $61M | $3.64T |
| P/E | 10.1 | 25.2 |
| P/E, 5-year median | 15.9 | 35.2 |
| P/B | 1.3 | 7.6 |
| EV/EBIT | 2.2 | 22.3 |
| Free cash flow yield | 5.0% | 1.7% |
| Revenue, 12 months | $64M | $346B |
|---|---|---|
| Net income, 12 months | $23M | $143B |
| Free cash flow, 12 months | $12M | $60.0B |
| Earnings per share, 12 months | $0.46 | $19.16 |
| Revenue growth, year on year | 5.2% | 17.8% |
| Revenue growth a year, past | +5.4%over 2 years | +14.6%over 5 years |
| EPS growth a year, past | +0.0%over 2 years | +17.4%over 5 years |
| Gross margin | 82.9% | 67.7% |
|---|---|---|
| Operating margin | 43.4% | 47.1% |
| Net margin | 36.0% | 41.2% |
| ROIC | 11.7% | 28.7% |
| ROE | 12.3% | 34.3% |
| Cash | $174M | $64.5B |
|---|---|---|
| Total debt | $1.3M | $134B |
| Net debt / EBITDA | -6.2 | 0.2 |
| Interest cover | – | 50.6× |
| Dividend yield | 0.7% | 0.8% |
|---|---|---|
| Dividend per share, 12 months | $0.03 | $3.71 |
| Dividend growth a year, past | – | +10.2%over 5 years |
| Buyback yield | – | 0.6% |
| Shareholder yield | 0.7% | 1.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Microsoft ($3.59T) is about 15,294.5 times Clinuvel Pharmaceuticals ($235M), at today's prices.
Since November 21, 2016, CUVL's price moved -22.3% and MSFT's +695.3%. With dividends: CUVL -20.9% (-2.3% a year), MSFT +791.5% (+24.5% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.71% for Clinuvel Pharmaceuticals and 0.77% for Microsoft. Over the last twelve months they paid $0.03 and $3.71 per share.
At today's price, the P/E is 10.1 for CUVL and 25.2 for MSFT. The median of the last five years was 15.9 and 35.2, which shows where each stands against its own past.
Over the last twelve months, the net margin was 36.0% for Clinuvel Pharmaceuticals and 41.2% for Microsoft, and the operating margin 43.4% and 47.1%. Revenue was $64M and $346B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.